Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAVO412 in Advanced or Metastatic Solid Tumors
NCT05548634Phase 1Active, not recruiting
- Sponsor
- Tavotek Biotherapeutics
- Start
- May 2023
- Primary completion
- Dec 2025
- Modality
- Antibody Conjugates, Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of tavo412 in solid tumor, gastric cancer (GC) and non-small cell lung cancer (NSCLC) (7 arms), sponsored by Tavotek Biotherapeutics. Primary endpoint: Safety and Tolerability of TAVO412 according to Adverse Events and Number of Participants With Dose Limiting Toxicity (DLT) at 12 months. Started May 2023; status: active, not recruiting.
02
Drugs
tavo412
03
Conditions
solid tumorgastric cancer (GC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05548634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05548634.